Limits...
oligoclonal bands in patients with multiple myeloma: its emergence per se could not be translated to improved survival.

Fujisawa M, Seike K, Fukumoto K, Suehara Y, Fukaya M, Sugihara H, Takeuchi M, Matsue K - Cancer Sci. (2014)

Bottom Line: However, if the patients were limited to ≥VGPR or CR, development of OB did not affect PFS (P = 0.621 and P = 0.646, respectively) or OS (P = 0.189 and P = 0.766, respectively).OB was observed in 60% of patients after SCT, and in 36.6% of patients with more than VGPR without SCT (P < 0.001).In conclusion, the emergence of OB was seen exclusively in patients with favorable responses, but its emergence per se could not be translated to improved survival.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan.

Show MeSH

Related in: MedlinePlus

Progression-free survival (a) and overall survival (b) rates of patients who obtained complete response (CR) according to the presence or absence of oligoclonal band (OB).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4462372&req=5

fig03: Progression-free survival (a) and overall survival (b) rates of patients who obtained complete response (CR) according to the presence or absence of oligoclonal band (OB).

Mentions: Next, we examined the prognostic impact of developing OB. The clinical outcome was compared between patients with and without OB. Figure 2 shows PFS and OS of all cohorts. The median PFS and OS of the patients with or without OB were 79.4 and 19.2 months (P=0.028), and not reached and 41.1 months, respectively. Consistent with previous studies, patients with OB showed better PFS and OS compared to those without OB. These observations indicated that the development of OB is a favorable prognostic factor for survival. However, as shown in Table 1, the development of OB was closely linked to favorable response, such as CR or VGPR, and, therefore, we compared PFS and OS among patients who achieved CR (Fig. 3). Median PFS and OS of CR patients with and without OB were not significantly different between the two groups (79.4 vs 80.1 months, respectively, P = 0.646; and not reached and not reached, respectively, P = 0.776). If the patients were analyzed better than VGPR, results were similar with CR patients (data not shown). These observations indicated that OB appeared exclusively in the patients with better than VGPR response; however, there was no correlation between emergence of an oligoclonal band and survival in these patients.


oligoclonal bands in patients with multiple myeloma: its emergence per se could not be translated to improved survival.

Fujisawa M, Seike K, Fukumoto K, Suehara Y, Fukaya M, Sugihara H, Takeuchi M, Matsue K - Cancer Sci. (2014)

Progression-free survival (a) and overall survival (b) rates of patients who obtained complete response (CR) according to the presence or absence of oligoclonal band (OB).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4462372&req=5

fig03: Progression-free survival (a) and overall survival (b) rates of patients who obtained complete response (CR) according to the presence or absence of oligoclonal band (OB).
Mentions: Next, we examined the prognostic impact of developing OB. The clinical outcome was compared between patients with and without OB. Figure 2 shows PFS and OS of all cohorts. The median PFS and OS of the patients with or without OB were 79.4 and 19.2 months (P=0.028), and not reached and 41.1 months, respectively. Consistent with previous studies, patients with OB showed better PFS and OS compared to those without OB. These observations indicated that the development of OB is a favorable prognostic factor for survival. However, as shown in Table 1, the development of OB was closely linked to favorable response, such as CR or VGPR, and, therefore, we compared PFS and OS among patients who achieved CR (Fig. 3). Median PFS and OS of CR patients with and without OB were not significantly different between the two groups (79.4 vs 80.1 months, respectively, P = 0.646; and not reached and not reached, respectively, P = 0.776). If the patients were analyzed better than VGPR, results were similar with CR patients (data not shown). These observations indicated that OB appeared exclusively in the patients with better than VGPR response; however, there was no correlation between emergence of an oligoclonal band and survival in these patients.

Bottom Line: However, if the patients were limited to ≥VGPR or CR, development of OB did not affect PFS (P = 0.621 and P = 0.646, respectively) or OS (P = 0.189 and P = 0.766, respectively).OB was observed in 60% of patients after SCT, and in 36.6% of patients with more than VGPR without SCT (P < 0.001).In conclusion, the emergence of OB was seen exclusively in patients with favorable responses, but its emergence per se could not be translated to improved survival.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan.

Show MeSH
Related in: MedlinePlus